FDA REMS restrictions keep limiting mifepristone after Dobbs

The Trump administration's FDA maintained and tightened Risk Evaluation and Mitigation Strategy restrictions on mifepristone, requiring in-person dispensing and provider certification despite the Supreme Court's Dobbs ruling returning abortion regulation to states. The REMS framework blocked telehealth prescribing and mail-order pharmacy dispensing in states where abortion remains legal. Reproductive rights advocates argued the restrictions exceeded FDA's statutory authority under the Food, Drug, and Cosmetic Act.